For people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), what are the effects of CD19-targeted chimeric antigen receptor (CAR) T-cell therapy?

2021 ◽  
Author(s):  
Jane Burch ◽  
Sera Tort
Keyword(s):  
Cell Therapy ◽  
B Cell ◽  
Chimeric Antigen Receptor ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
T Cell Therapy ◽  
Large B Cell Lymphoma ◽  
Car T Cell Therapy ◽  
Car T ◽  
Large B Cell

Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma

2021 ◽  
Vol 2021 (9) ◽  
Author(s):  
Moritz Ernst ◽  
Annika Oeser ◽  
Burcu Besiroglu ◽  
Julia Caro-Valenzuela ◽  
Mohamed Abd El Aziz ◽  
...  
Keyword(s):  
Cell Therapy ◽  
B Cell ◽  
Chimeric Antigen Receptor ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
T Cell Therapy ◽  
Large B Cell Lymphoma ◽  
Car T Cell Therapy ◽  
Car T ◽  
Large B Cell

scholarly journals Rapid relapse of large B‐cell lymphoma after CD19 directed CAR‐T‐cell therapy due to CD‐19 antigen loss

2019 ◽  
Vol 94 (10) ◽  
Author(s):  
Ali Bukhari ◽  
Firas El Chaer ◽  
Rima Koka ◽  
Zeba Singh ◽  
Elizabeth Hutnick ◽  
...  
Keyword(s):  
Cell Therapy ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
T Cell Therapy ◽  
Large B Cell Lymphoma ◽  
Car T Cell Therapy ◽  
Car T ◽  
Antigen Loss ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document